Department of Translational Oncology, Genentech, Inc., South San Francisco, California.
Curr Protoc. 2022 Mar;2(3):e377. doi: 10.1002/cpz1.377.
Murine tumor modeling is fundamental for the preclinical development of anti-cancer therapies. Use of immunocompetent mouse models is becoming increasingly relevant as we gain more knowledge of how cancer cells interact with the immune system in the tumor microenvironment and how we can harness the immune system to fight tumors. However, there are few intrinsically immunogenic preclinical tumor models, and the vast majority either do not respond to therapy or do not faithfully predict the responses of the therapy when applied in the clinic. Here, we discuss the limitations of commonly used murine tumor models in immuno-oncology and strategies to improve their immunogenicity and mutational burden to more accurately reflect the heterogeneity of patient tumors. © 2022 Wiley Periodicals LLC.
鼠类肿瘤模型是癌症治疗药物临床前开发的基础。随着我们对癌细胞在肿瘤微环境中如何与免疫系统相互作用以及如何利用免疫系统对抗肿瘤有了更多的了解，免疫功能健全的小鼠模型的应用变得越来越重要。然而，具有固有免疫原性的临床前肿瘤模型很少，绝大多数要么对治疗没有反应，要么在临床上应用时不能准确预测治疗的反应。在这里，我们讨论了在肿瘤免疫治疗中常用的鼠类肿瘤模型的局限性，以及提高其免疫原性和突变负担的策略，以更准确地反映患者肿瘤的异质性。© 2022 年 Wiley 期刊 LLC。
